Literature DB >> 17015756

Human CD4+ T cells lyse target cells via granzyme/perforin upon circumvention of MHC class II restriction by an antibody-like immunoreceptor.

Andreas Hombach1, Heike Köhler, Gunter Rappl, Hinrich Abken.   

Abstract

Immune elimination of tumor cells requires the close cooperation between CD8+ CTL and CD4+ Th cells. We circumvent MHC class II-restriction of CD4+ T cells by expression of a recombinant immunoreceptor with an Ab-derived binding domain redirecting specificity. Human CD4+ T cells grafted with an immunoreceptor specific for carcinoembryonic Ag (CEA) are activated to proliferate and secrete cytokines upon binding to CEA+ target cells. Notably, redirected CD4+ T cells mediate cytolysis of CEA+ tumor cells with high efficiencies. Lysis by redirected CD4+ T cells is independent of death receptor signaling via TNF-alpha or Fas, but mediated by perforin and granzyme because cytolysis is inhibited by blocking the release of cytotoxic granules, but not by blocking of Fas ligand or TNF-alpha. CD4+ T cells redirected by Ab-derived immunoreceptors in a MHC class II-independent fashion substantially extend the power of an adoptive, Ag-triggered immunotherapy not only by CD4+ T cell help, but also by cytolytic effector functions. Because cytolysis is predominantly mediated via granzyme/perforin, target cells that are resistant to death receptor signaling become sensitive to a cytolytic attack by engineered CD4+ T cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17015756     DOI: 10.4049/jimmunol.177.8.5668

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  32 in total

Review 1.  New Strategies in Engineering T-cell Receptor Gene-Modified T cells to More Effectively Target Malignancies.

Authors:  Thomas M Schmitt; Ingunn M Stromnes; Aude G Chapuis; Philip D Greenberg
Journal:  Clin Cancer Res       Date:  2015-10-13       Impact factor: 12.531

Review 2.  Prospects of chimeric antigen receptor T cell therapy in ovarian cancer.

Authors:  Vishal Jindal; Ena Arora; Sorab Gupta; Amos Lal; Muhammad Masab; Rashmika Potdar
Journal:  Med Oncol       Date:  2018-04-12       Impact factor: 3.064

3.  Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies.

Authors:  Carlos A Ramos; Neeharika Narala; Gayatri M Vyas; Ann M Leen; Ulrike Gerdemann; Erich M Sturgis; Matthew L Anderson; Barbara Savoldo; Helen E Heslop; Malcolm K Brenner; Cliona M Rooney
Journal:  J Immunother       Date:  2013-01       Impact factor: 4.456

4.  Tumor-infiltrating HLA-matched CD4(+) T cells retargeted against Hodgkin and Reed-Sternberg cells.

Authors:  Benjamin Rengstl; Frederike Schmid; Christian Weiser; Claudia Döring; Tim Heinrich; Kathrin Warner; Petra S A Becker; Robin Wistinghausen; Sima Kameh-Var; Eva Werling; Arne Billmeier; Christian Seidl; Sylvia Hartmann; Hinrich Abken; Ralf Küppers; Martin-Leo Hansmann; Sebastian Newrzela
Journal:  Oncoimmunology       Date:  2016-03-16       Impact factor: 8.110

5.  T Cell Reprogramming Against Cancer.

Authors:  Samuel G Katz; Peter M Rabinovich
Journal:  Methods Mol Biol       Date:  2020

Review 6.  Role of Chimeric Antigen Receptor T Cell Therapy in Glioblastoma Multiforme.

Authors:  Vishal Jindal
Journal:  Mol Neurobiol       Date:  2018-03-09       Impact factor: 5.590

Review 7.  Chimeric antigen receptor T cell therapy in pancreatic cancer: from research to practice.

Authors:  Vishal Jindal; Ena Arora; Muhammad Masab; Sorab Gupta
Journal:  Med Oncol       Date:  2018-05-04       Impact factor: 3.064

8.  Role of perforin-mediated cell apoptosis in murine models of infusion-induced bone marrow failure.

Authors:  Annahita K Sarcon; Marie J Desierto; Wenjun Zhou; Valeria Visconte; Federica Gibellini; Jichun Chen; Neal S Young
Journal:  Exp Hematol       Date:  2009-02-12       Impact factor: 3.084

9.  Exploration of the lysis mechanisms of leukaemic blasts by chimaeric T-cells.

Authors:  David Laurin; Virna Marin; Ettore Biagi; Irene Pizzitola; Valentina Agostoni; Géraldine Gallot; Henri Vié; Marie Christine Jacob; Laurence Chaperot; Caroline Aspord; Joël Plumas
Journal:  J Biomed Biotechnol       Date:  2010-06-13

Review 10.  Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.

Authors:  Marc Cartellieri; Michael Bachmann; Anja Feldmann; Claudia Bippes; Slava Stamova; Rebekka Wehner; Achim Temme; Marc Schmitz
Journal:  J Biomed Biotechnol       Date:  2010-05-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.